Based on this observation, we examined the immunological consequences of RB1 loss in prostate tumor cells and whether targeted therapeutics aimed at reversing the molecular consequences of RB1 loss (namely inhibitors of the bromodomain and extraterminal (BET) domain family of proteins) can reprogram the immune phenotype of Rb-deficient tumors. Here, RB1 is linked to prostate neoplasm.